UNLABELLED: Hyperandrogenism and hyperinsulinism have both been suggested as etiologic factors behind functional ovarian hyperandrogenism or polycystic ovary syndrome. Females with congenital adrenal hyperplasia provide a clinical model to evaluate the contribution of pre- and post-natal hyperandrogenism on ovarian structure and function. STUDY OBJECTIVE: To evaluate glucose tolerance, and structure and androgen production of the ovaries in young females with classic congenital adrenal hyperplasia. DESIGN, SETTING, PARTICIPANTS: Cross-sectional study, including the enrollment of participants, ages 8 to 20 years, recruited from the pediatric endocrinology clinical program of a tertiary pediatric referral center. INTERVENTIONS: Ten participants had oral glucose tolerance testing, adrenal and ovarian androgen measurements, and pelvic ultrasound studies performed. MAIN OUTCOME MEASURES: Presence of altered response to glucose challenge, ovarian hyperandrogenism, or presence of polycystic ovaries by ultrasound. RESULTS: Measurements of fasting blood glucose, post-challenge glucose, and insulin resistance were normal in this sample. There was no evidence of ovarian hyperandrogenism after adrenal suppression with dexamethasone. All participants had normal ovarian structure without evidence of polycystic ovaries. CONCLUSIONS: Females with classic congenital adrenal hyperplasia (21-hydroxylase deficiency) and normal glucose tolerance appear to have normal ovarian structure and function during the peripubertal period.
UNLABELLED: Hyperandrogenism and hyperinsulinism have both been suggested as etiologic factors behind functional ovarian hyperandrogenism or polycystic ovary syndrome. Females with congenital adrenal hyperplasia provide a clinical model to evaluate the contribution of pre- and post-natal hyperandrogenism on ovarian structure and function. STUDY OBJECTIVE: To evaluate glucose tolerance, and structure and androgen production of the ovaries in young females with classic congenital adrenal hyperplasia. DESIGN, SETTING, PARTICIPANTS: Cross-sectional study, including the enrollment of participants, ages 8 to 20 years, recruited from the pediatric endocrinology clinical program of a tertiary pediatric referral center. INTERVENTIONS: Ten participants had oral glucose tolerance testing, adrenal and ovarian androgen measurements, and pelvic ultrasound studies performed. MAIN OUTCOME MEASURES: Presence of altered response to glucose challenge, ovarian hyperandrogenism, or presence of polycystic ovaries by ultrasound. RESULTS: Measurements of fasting blood glucose, post-challenge glucose, and insulin resistance were normal in this sample. There was no evidence of ovarian hyperandrogenism after adrenal suppression with dexamethasone. All participants had normal ovarian structure without evidence of polycystic ovaries. CONCLUSIONS: Females with classic congenital adrenal hyperplasia (21-hydroxylase deficiency) and normal glucose tolerance appear to have normal ovarian structure and function during the peripubertal period.
Authors: Gabriel I Uwaifo; Erica M Fallon; Jeff Chin; Jane Elberg; Shamik J Parikh; Jack A Yanovski Journal: Diabetes Care Date: 2002-11 Impact factor: 19.112
Authors: Mark R Palmert; Catherine M Gordon; Alex I Kartashov; Richard S Legro; S Jean Emans; Andrea Dunaif Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958
Authors: E Bonora; G Targher; M Alberiche; R C Bonadonna; F Saggiani; M B Zenere; T Monauni; M Muggeo Journal: Diabetes Care Date: 2000-01 Impact factor: 19.112
Authors: Evangelia Charmandari; Martina Weise; Stefan R Bornstein; Graeme Eisenhofer; Margaret F Keil; George P Chrousos; Deborah P Merke Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: R B Barnes; R L Rosenfield; D A Ehrmann; J F Cara; L Cuttler; L L Levitsky; I M Rosenthal Journal: J Clin Endocrinol Metab Date: 1994-11 Impact factor: 5.958
Authors: Phyllis W Speiser; Ricardo Azziz; Laurence S Baskin; Lucia Ghizzoni; Terry W Hensle; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; Victor M Montori; Sharon E Oberfield; Martin Ritzen; Perrin C White Journal: J Clin Endocrinol Metab Date: 2010-09 Impact factor: 5.958